Peptide reference

25% weight loss in Phase 3. No plateau at 80 weeks. GIP + GLP-1 + glucagon.

22.5% weight loss (SURMOUNT). FDA-approved. GIP + GLP-1 dual mechanism.

C-terminal GH fragment. Stimulates lipolysis without IGF-1 elevation.

Tendon, muscle, and gut repair. Derived from human gastric juice. 4-hour half-life.

Thymosin beta-4 fragment. Actin upregulation, angiogenesis, cell migration.

GHRH analogue. Without DAC: 30-min half-life. With DAC: 8-day half-life.

Selective GH secretagogue. No cortisol or prolactin spike. 2-hour half-life.

Synthetic GHRH 1-29 fragment. Natural pituitary stimulation. 10-min half-life.

FDA-approved GHRH analog (Egrifta). Stimulates endogenous GH, reduces visceral fat.

Master regulator of the HPG axis. Drives pulsatile LH and testosterone through GnRH.

Collagen synthesis, wound healing, stem cell activation. Naturally occurring.

Tetrapeptide. Telomere elongation, pineal regulation. Longevity research.

Bremelanotide. MC3R/MC4R agonist. FDA-approved (Vyleesi). Central action.

Mitochondria-derived peptide. AMPK activation, insulin sensitivity, anti-aging.